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ABSTRACT
Objectives Autoantibodies directed against cytosolic
50-nucleotidase 1A have been identiﬁed in many patients
with inclusion body myositis. This retrospective study
investigated the association between anticytosolic 50-
nucleotidase 1A antibody status and clinical, serological
and histopathological features to explore the utility of
this antibody to identify inclusion body myositis
subgroups and to predict prognosis.
Materials and methods Data from various
European inclusion body myositis registries were pooled.
Anticytosolic 50-nucleotidase 1A status was determined
by an established ELISA technique. Cases were stratiﬁed
according to antibody status and comparisons made.
Survival and mobility aid requirement analyses were
performed using Kaplan-Meier curves and Cox
proportional hazards regression.
Results Data from 311 patients were available for
analysis; 102 (33%) had anticytosolic 50-nucleotidase
1A antibodies. Antibody-positive patients had a higher
adjusted mortality risk (HR 1.89, 95% CI 1.11 to 3.21,
p=0.019), lower frequency of proximal upper limb
weakness at disease onset (8% vs 23%, adjusted OR
0.29, 95% CI 0.12 to 0.68, p=0.005) and an increased
prevalence of excess of cytochrome oxidase deﬁcient
ﬁbres on muscle biopsy analysis (87% vs 72%, adjusted
OR 2.80, 95% CI 1.17 to 6.66, p=0.020), compared
with antibody-negative patients.
Interpretation Differences were observed in clinical
and histopathological features between anticytosolic 50-
nucleotidase 1A antibody positive and negative patients
with inclusion body myositis, and antibody-positive
patients had a higher adjusted mortality risk.
Stratiﬁcation of inclusion body myositis by anticytosolic
50-nucleotidase 1A antibody status may be useful,
potentially highlighting a distinct inclusion body myositis
subtype with a more severe phenotype.
INTRODUCTION
Inclusion body myositis (IBM) is an acquired muscle
disease that most commonly affects males aged over
45 years. Along with polymyositis (PM) and derm-
atomyositis (DM), IBM is usually classiﬁed as one of
the idiopathic inﬂammatory myopathies. However,
IBM differs in comparison with PM and DM, as sus-
tained responses to immunosuppression are not
seen, and histologically it is associated with signiﬁ-
cant degenerative features.1–3 Clinically, IBM is
characterised by asymmetric weakness, notably of
ﬁnger ﬂexors and knee extensors. Weakness in other
muscle groups occurs frequently, including bulbar,
facial and axial muscles.4 5 The slowly progressive
course leads to cumulative disability, although
overall life expectancy is unaffected.6–8
The diagnosis of IBM relies upon a combination
of clinical and laboratory ﬁndings as deﬁned in
various diagnostic criteria (eg, Medical Research
Council (MRC), Griggs et al and the European
Neuromuscular Centre (ENMC) criteria).9–11
However, certain histopathological ﬁndings may
only become detectable as the disease progresses,
and therefore patients with early disease may not
fulﬁl deﬁnite diagnostic criteria and can be
excluded from clinical trials.12 The average delay
between disease onset and diagnosis is around
5 years, and IBM is frequently misdiagnosed ini-
tially as PM, resulting in the unnecessary use of
potentially harmful treatments, such as high-dose
glucocorticoids.8 13–15
In IBM, autoantibodies directed against cytosolic
50-nucleotidase 1A (cN-1A) have recently been iden-
tiﬁed. It is suggested that these may support the
diagnostic process, as well as potentially providing
clues as to disease pathogenesis.16 17 However,
uncertainties regarding the usefulness of anti-cN-1A
autoantibody testing in clinical practice remain. This
is particularly true with regard to patient stratiﬁca-
tion and prognosis, where the few studies that have
compared clinical and histopathological features of
antibody-positive versus antibody-negative patients
with IBM have produced conﬂicting results in some
cases.18 19 In order to explore further the usefulness
of anti-cN-1A antibody testing to facilitate IBM sub-
group classiﬁcation, we conducted a retrospective
Europe-wide study correlating clinical, serological
and histopathological features in a large cohort of
patients with IBM stratiﬁed by anti-cN-1A antibody
status.
PATIENTS AND METHODS
Study cohort
Pooled IBM case data from four European coun-
tries were used. Researchers based in Nijmegen,
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The Netherlands, coordinated data collection from The
Netherlands, France and Sweden. Data collection in the UK was
coordinated by researchers based in Manchester, UK.
Study inclusion criteria
Included cases met either the MRC (‘pathologically deﬁned’,
‘clinically deﬁned’ or ‘possible’), Griggs et al (‘deﬁnite’ or ‘pos-
sible’) or ENMC (‘clinicopathologically deﬁned’, ‘clinically
deﬁned’ or ‘probable’) diagnostic criteria for IBM and had sera
available for anti-cN-1A antibody testing.9 11
Data collection methodology
Swedish, French and Dutch (‘non-UK’) patients were identiﬁed
from clinical databases. Researchers blinded to anti-cN-1A anti-
body status (AR, MTJP, KRG, KM) reviewed the medical
records and retrospectively completed a standardised data col-
lection pro forma. UK patients were identiﬁed from six centres
contributing to the UKMYONET research study, coordinated by
The University of Manchester. As part of this study, data are
captured using a standardised pro forma at the time of study
recruitment (ie, before serological test results are available).20 21
Those recruiting patients are asked to record clinical features
present at disease onset and features present at the time of
recruitment. Some additional ﬁelds (to match data from the
non-UK cohort) and missing data were collected retrospectively.
Copies of pro forma used are contained in online
supplementary appendix 1. The datasets were merged and
cleaned by a researcher blinded to anti-cN-1A status ( JBL).
Clinical data
Data collected included demographic, clinical (eg, distribution
of weakness, presence of dysphagia, comorbidities), laboratory
ﬁndings (creatine kinase (CK) levels, muscle biopsy features,
serological testing), comorbidity, mobility aid usage and mortal-
ity. In most cases, data were available regarding features present
at disease onset and at the time of last patient review (or recruit-
ment to the UKMYONET study in the case of the UK cohort).
In all cases, ‘disease onset’ refers to the initial date that symp-
toms of IBM were noted, as reported by the patient. ‘Disease
duration’ is deﬁned as the period between disease onset and the
date of anti-cN-1A antibody testing. Regarding mortality, in the
non-UK cohort, the primary cause of death was categorised by
review of the patient’s medical records as either ‘respiratory’,
‘cardiac’, ‘cerebrovascular’, ‘malignancy’ or ‘other’. In the UK
cohort, additional mortality and comorbidity statistics were
obtained from the UK Health and Social Care Information
Centre, including coded data regarding the cause of death
where applicable. The cause of death in these cases was assessed
and assigned to the same categories as the non-UK cohort.
Histopathology
For all cases, the histopathology biopsy report performed at
initial diagnostic interrogation was reviewed, and the presence
of certain speciﬁc features determined from the report text. The
reporting histopathologists were blinded to the anti-cN-1A anti-
body status of each patient at the time of reporting.
Cytochrome oxidase (COX) deﬁcient ﬁbres in the biopsy sample
were recorded as ‘excessive’ if the reporting histopathologist
indicated that numbers were adjudged higher than expected,
according to the patient’s age. In some cases, the date that the
biopsy was performed was not available. In such instances, this
was assumed to be the same as the date of diagnosis.
cN-1A analysis
All sera were analysed at the Department of Biomolecular
Chemistry in Nijmegen by ELISA, with the three synthetic pep-
tides containing cN-1A autoepitopes previously identiﬁed by
overlapping peptide microarray analyses.16 Signals were quanti-
ﬁed by determining optical densities at 450 nm (OD450) using
methods previously described and deﬁned as seropositive if the
OD450 value was greater than or equal to the established
cut-off value for the corresponding peptide.22
Other serological testing
Data regarding the presence of myositis-speciﬁc antibodies
(MSAs) and myositis-associated antibodies (MAAs) were col-
lected where available. For the non-UK patients, data were
obtained from results available in the medical records, and
methodology of testing was unique to each centre. MSAs and
MAAs in the whole UK cohort were screened by immunopreci-
pitation at the University of Bath (Bath, UK) using previously
described standardised methodology.23 ‘Weak positive’ results
were assumed to be negative for the purpose of this study.
Statistical analysis
The per-subject sum of all recorded comorbidities (of auto-
immune disease, cardiovascular disease (including hypertension)
and malignancy) was calculated. Current or previous smoking
was also treated as a comorbidity for the purposes of this ana-
lysis. According to the number of these factors present, each
patient was then assigned a comorbidity score of 0, 1 or 2 or
more for use in regression. Differences in demographic features,
comorbidities, clinical features, autoantibody status and muscle
biopsy features between anti-cN-1A antibody positive and nega-
tive patients were assessed using logistic regression. In order to
test the effect of potential confounders, adjusted (multivariable)
logistic regression models were produced when unadjusted ana-
lysis had suggested a signiﬁcant difference (deﬁned as p<0.05).
The impact of anti-cN-1A antibody status on survival and
mobility aid requirement was assessed using Kaplan-Meier
curves, log-rank testing and Cox proportional hazards regression
modelling. In both cases, the start of the surveillance period was
the date of disease onset. For the mobility aid analysis, subjects
exited the model at the time of mobility aid requirement or at
the time they were last known to have not required one. For the
survival analysis, subjects exited the model at the time of death
or at the time they were last known to have been alive. Each
Cox regression model included adjustment for age of disease
onset, gender and comorbidities. Other variables were added to
the models if there was an a priori assumption that a relation-
ship between anti-cN-1A antibody status and the outcome vari-
able was likely to exist. For example, a higher incidence of
anti-cN-1A antibodies in those with Sjögren’s syndrome is
reported, a more prominent bulbar involvement in anti-cN-1A
positive patients with IBM has been described and a correlation
between COX deﬁciency and more advanced age at biopsy
could exist.18 22 24 Therefore, models with additional adjust-
ment for such variables were created.
The analysis plan speciﬁcally omitted correction for multiple
testing due to the highly conservative nature of such methods
which would risk elimination of potentially useful information
which was sought to be retained, given the exploratory nature
of this study. Data were processed and analysed using Stata for
Windows V.13.0 (College Station, Texas, USA). Kaplan-Meier
curves were generated using GraphPad Prism V.6 (GraphPad
Software).
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RESULTS
After screening databases in the four involved countries, 311
patients meeting the study inclusion criteria were selected for
further analysis (45% from the UK, 55% non-UK). Overall,
33% (102/311) were positive for the anti-cN-1A antibody.
Table 1 shows the IBM diagnostic criteria met according to
anti-cN-1A antibody status. No relationship between a diagnos-
tic classiﬁcation of ‘possible’ IBM versus ‘deﬁnite’ (for Griggs
et al criteria) or ‘pathologically/clinically deﬁned’ (for MRC cri-
teria) IBM and anti-cN-1A antibody status was found (for MRC
criteria, OR 0.85, 95% CI 0.48 to 1.49, p=0.565; for Griggs
et al criteria, OR 0.70, 95% CI 0.36 to 1.36, p=0.292; analysis
not performed for ENMC criteria as all anti-cN-1A antibody
positive patients met the deﬁnition of ‘deﬁnite’ IBM). No differ-
ence was found in the interval between disease onset and the
time of antibody testing between seropositive and seronegative
groups (8.29 years (IQR 4.96–11.95) in the seropositive group
vs 7.57 years (IQR 4.94–11.18) in the seronegative group, OR
1.01, 95% CI 0.97 to 1.06, p=0.604).
Demographics and comorbidities
No statistically signiﬁcant differences were identiﬁed in demo-
graphic characteristics (including gender, age at disease onset
and age at diagnosis), CK levels, smoking history or comorbid-
ities between the anti-cN-1A antibody positive and negative
groups (table 2). Non-signiﬁcant trends were observed in age at
disease onset and age at diagnosis (which appeared lower in the
antibody-negative group) or the presence of other autoimmune
diseases (which appeared more common in the antibody-
positive group).
Survival
Of the whole cohort of 311 patients, 70 deaths were recorded
(31/102 (30%) in the anti-cN-1A antibody positive group and
39/209 (19%) in the negative group). The mean age of death
overall was 77.8 years (SD=8.2), with no signiﬁcant difference
detected according to anti-cN-1A antibody status (77.0 years
(SD=7.7) in the seropositive group vs 78.4 years (SD=8.6) in
the seronegative group, OR 0.98, 95% CI 0.92 to 1.04,
p=0.482). The cause of death was known in 63% (44 of 70) of
cases. An excess of deaths as a result of respiratory disease was
evident in the anti-cN-1A antibody positive group (16/25 (64%)
in the anti-cN-1A antibody positive group and 9/25 (36%) in
the negative group, OR 4.23, 95% CI 1.79 to 9.97, p=0.001).
Adjusted analysis was not performed here due to the low
numbers available for analysis. Death from other causes
(cardiac, cerebrovascular, malignancy and other causes) did not
differ between anti-cN-1A antibody positive and negative
groups.
Data from 300 patients, where the date of disease onset and
date of last follow-up (or date of death) were known, were avail-
able for further analysis. This included 66 of those that had
died (66/70, 94%) and comprised a total of 3550 patient-years
of follow-up. The median survival in the anti-cN-1A antibody
positive group was 17.6 years compared with 24.2 years in the
antibody-negative group, and the Kaplan-Meier curves were sig-
niﬁcantly different (log-rank p=0.045, ﬁgure 1).
In unadjusted analysis, compared with the antibody-negative
group, anti-cN-1A antibody positive patients had a 65%
increased risk of death (HR 1.65, 95% CI 1.01 to 2.70,
p=0.047). After adjustment for age at disease onset, gender and
comorbidities, the HR was 1.95 (95% CI 1.17 to 3.27,
p=0.011). Furthermore, adding the presence of dysphagia to
the model conﬁrmed an independent association (HR 1.89,
95% CI 1.11 to 3.21, p=0.019).
Mobility
Data from 188 patients were available for this analysis. A total
of 130 instances of mobility aid uptake were recorded, 81%
(52/64) in the anti-cN-1A seropositive group and 63% (78/124)
in the seronegative group. The overall median time between
disease onset and use of a mobility aid was 8.0 years (IQR 4.6–
11.0), with no signiﬁcant difference between seropositive and
seronegative groups (8.0 years (IQR 4.8–10.9), and 6.9 years
(IQR 4.4–11.7), respectively; OR 1.01, 95% CI 0.94 to 1.08,
p=0.883). Kaplan-Meier curves were not signiﬁcantly different
(log-rank p=0.090), so not shown. In unadjusted analysis, the
HR for mobility aid requirement in the antibody-positive group
was 1.35 (95% CI 0.95 to 1.93, p=0.097). After adjustment for
age at disease onset, gender and comorbidities, the HR for
mobility aid requirement was just outside the signiﬁcance
threshold (HR 1.42, 95% CI 0.99 to 2.04, p=0.056).
Clinical features
Table 3 demonstrates the clinical characteristics at disease onset
and at last clinical review, stratiﬁed by anti-cN-1A antibody
status. A signiﬁcant association between the presence of prox-
imal upper limb weakness at disease onset (not a typical feature
of IBM) and being anti-cN-1A antibody negative was identiﬁed
(OR 0.30 95% CI 0.13 to 0.71, p=0.006). This remained sig-
niﬁcant after adjustment for age at onset, gender and comorbid-
ities (OR 0.29, 95% CI 0.12 to 0.68, p=0.005), thus
potentially deﬁning a more classical and homogenous IBM
cohort in the anti-cN-1A antibody positive group. Data regard-
ing the presence of facial weakness were less complete (n=90).
Despite this, a signiﬁcantly increased incidence of facial weak-
ness was identiﬁed in the anti-cN-1A antibody positive group at
last review (OR 2.60, 95% CI 1.07 to 6.29, p=0.034), which
persisted after adjustment for age at onset, gender and
comorbidities (OR 3.03, 95% CI 1.20 to 7.67, p=0.019).
Autoantibody associations
A signiﬁcant association between seropositivity for anti-SSB (La)
antibodies and anti-cN-1A antibodies was identiﬁed (OR 3.28,
95% CI 1.33 to 8.07, p=0.010) (table 4). However, adjusted
Table 1 Summary of diagnostic criteria met in patients included for
analysis
Diagnostic criteria met
Anti-cN-1A
positive (%)
Total
(all patients)
Medical Research Council Criteria 201010
Pathologically defined IBM 13 (31.7) 41
Clinically defined IBM 39 (39.4) 99
Possible IBM 28 (33.3) 84
Griggs et al9 Criteria
Definite IBM 19 (40.4) 47
Possible IBM 61 (32.3) 189
European Neuromuscular Centre Criteria 199711
Definite IBM 7 (31.8) 22
Probable IBM 0 (0.0) 2
Total unique patients* 102 (32.8) 311
*Some patients fulfilled multiple diagnostic criteria. Not all patients were assessed by
each criterion. Of the total, 152 patients met only one criterion, 143 patients met two
criteria and 16 patients met all three criteria.
Anti-cN-1A, anticytosolic 50-nucleotidase 1A; IBM, inclusion body myositis.
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analysis (for anti-SSA antibodies, presence of autoimmune disor-
ders, age at onset, gender and comorbidities) did not conﬁrm
that this association was independent (OR 2.12, 95% CI 0.52
to 8.67, p=0.297).
Biopsy features
We identiﬁed a signiﬁcant association between an excess of
COX-deﬁcient ﬁbres on muscle biopsy and the presence of
anti-cN-1A antibodies (OR 2.61, 95% CI 1.13 to 6.03,
p=0.025) (table 5). In adjusted analysis (for age at disease
onset, gender, comorbidities and age at biopsy), a signiﬁcant
independent association was conﬁrmed (OR 2.80, 95% CI 1.17
to 6.66, p=0.020).
DISCUSSION
This multinational exploratory study represents the ﬁrst of its
kind to combine analysis of clinical, histopathological, other
serological and mortality data in a large cohort of patients with
IBM stratiﬁed according to anti-cN-1A antibody status. Our
results will guide future conﬁrmatory studies and highlight
potential disease mechanisms warranting further evaluation. We
found that the anti-cN-1A antibody positive group had a signiﬁ-
cantly increased mortality risk independent of age, gender,
comorbidities and the presence of dysphagia. We also found a
smaller proportion with proximal upper limb weakness at
disease onset and an excess of COX-deﬁcient ﬁbres on muscle
biopsy in the anti-cN-1A antibody positive group. An increased
likelihood of having facial weakness and an association between
antibody positivity and death from a respiratory cause was also
observed, although the numbers assessed here were small. As in
other studies, we did not ﬁnd a relationship between disease
duration and the likelihood of identifying anti-cN-1A
antibodies.18 19
There are limited reports in the literature comparing the
characteristics of patients with IBM with and without
anti-cN-1A antibodies, amounting to 258 patients in four separ-
ate studies.18 19 24 25 A small proportion of the cases analysed
here was included in a previous analysis which did not focus on
differences on clinical characteristics according to serotype.22
Some authors identiﬁed no signiﬁcant differences in the
characteristics between cohorts, whereas others have suggested
that the anti-cN-1A antibody positive group exhibits a more
severe phenotype.18 19 Lloyd et al24 identiﬁed a lower incidence
of rimmed vacuoles on biopsy in those without anti-cN-1A
Table 2 Summary of demographic features, CK levels and comorbidities stratified by anti-cN-1A antibody status
Anti-cN-1A positive Anti-cN-1A negative OR (95% CI) p Value
Gender (n=311)
Female (%) 42/102 (41.2) 84/209 (40.2) Referent –
Male (%) 60/102 (58.8) 125/209 (59.8) 0.96 (0.59 to 1.55) 0.868
Ethnicity (n=307)
White (%) 97/101 (96.0) 199/206 (96.6) Referent –
Black (%) 2/101 (2.0) 4/206 (1.9) 1.03 (0.19 to 5.70) 0.977
Asian (%) 2/101 (2.0) 3/206 (1.5) 1.37 (0.23 to 8.32) 0.734
Other features
Mean age in years at disease onset (SD) (n=301) 61.6 (9.7) 59.8 (9.5) 1.02 (0.99 to 1.05) 0.130
Mean age in years at diagnosis (SD) (n=305) 67.2 (9.3) 65.3 (9.5) 1.02 (1.00 to 1.05) 0.089
Disease duration in years at antibody testing (n=301) Median 8.3 (IQR 5.0–12.0)
Mean 9.0 (SD 5.5)
Median 7.6 (IQR 4.9–11.2)
Mean 8.6 (SD 5.2)
1.01 (0.97 to 1.06) 0.604
Highest CK level recorded (n=223) Median 629.0
(IQR 392–850)
Mean 774.8 (SD 563.4)
Median 600.0 (IQR 400–1012)
Mean 1097.2 (SD 2583.4)
1.00 (1.00 to 1.00) 0.318
Current or previous smoker (%) (n=189) 21/52 (40.4) 55/137 (40.2) 1.01 (0.53 to 1.94) 0.976
Comorbidities
Autoimmune disease (including Sjögren’s syndrome) (%) (n=244) 38/85 (44.7) 54/159 (34.0) 1.57 (0.92 to 2.70) 0.100
Of which, Sjögren’s syndrome (%) (n=81) 6/33 (18.2) 8/48 (16.7) 1.11 (0.35 to 3.57) 0.859
Malignancy (%) (n=275) 12/85 (14.1) 33/190 (17.4) 0.78 (0.38 to 1.60) 0.501
Cardiovascular disease (%) (n=284) 31/91 (34.1) 64/193 (33.2) 1.04 (0.62 to 1.76) 0.880
Hypertension (%) (n=181) 29/60 (48.3) 54/121 (44.6) 1.16 (0.62 to 2.16) 0.638
‘Disease duration in years at antibody testing’ refers to the time period between disease onset and the date of anti-cN-1A antibody testing. n represents data available for analysis per
variable (of a total of 311). p Value is derived from logistic regression.
Anti-cN-1A, anticytosolic 50-nucleotidase 1A; CK, creatine kinase.
Figure 1 Kaplan-Meier survival curves stratiﬁed by anti-cN-1A
antibody status. X-axis truncated at 25 years from disease onset.
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reactivity but with no clinical differences between the studied
cohorts, ﬁndings that were not replicated here. A very recent
study found no differences between 24 cN-1A seropositive and
45 seronegative patients with IBM regarding class II human
leukocyte antigen (HLA) alleles and the presence of other
antibodies.25
The simultaneous discovery of anti-cN-1A antibodies in 2011
by two independent research groups offers potential insights
into the pathogenesis of IBM, and will contribute to the debate
about the relative inﬂuence of the immune system and degener-
ation.16 19 23 The presence of anti-cN-1A in other autoimmune
diseases such as Sjögren’s syndrome is also of interest as it might
highlight shared underlying immune mechanisms across these
diseases.22 As with most other MSAs, further research is
required to establish the mechanisms involved in anti-cN-1A
reactivity in IBM.
Anti-cN-1A antibodies are present in the sera of 29%–52% of
patients with IBM (33% in our cohort).16 17 Higher proportions
of anti-cN-1A antibody seropositivity in other studies (up to
72%) might be explained by different techniques used in differ-
ent centres, by different cut-off levels for positivity or by differ-
ences in patient selection.18 The current study used very strict
cut-off values in ELISA testing.26 In a recent study, anti-cN-1A
antibodies were found in 37% of patients with IBM, compared
with <5% in PM, DM and other neuromuscular disorders,
highlighting a potential utility of using anti-cN-1A antibody
Table 3 Clinical characteristics at disease onset and at last clinical review stratified by anti-cN-1A antibody status
Clinical feature Anti-cN-1A positive (%) Anti-cN-1A negative (%) OR (95% CI) p Value
At disease onset
Proximal upper limb weakness (n=252) 7/84 (8.3) 39/168 (23.2) 0.30 (0.13 to 0.71) 0.006*
Proximal lower limb weakness (n=253) 65/85 (76.5) 122/168 (72.6) 1.23 (0.67 to 2.24) 0.510
Distal upper limb weakness (n=251) 22/83 (26.5) 40/168 (23.8) 1.15 (0.63 to 2.11) 0.641
Distal lower limb weakness (n=250) 7/83 (8.4) 20/167 (12.0) 0.68 (0.27 to 1.67) 0.398
Dysphagia (n=119) 15/36 (41.7) 23/83 (27.7) 1.86 (0.82 to 4.22) 0.136
Axial involvement (n=102) 0/30 (0.0) 3/72 (4.2) 1 –
Symmetrical weakness (n=97) 25/37 (67.6) 32/60 (53.3) 1.82 (0.78 to 4.29) 0.169
At last review
Proximal lower limb weakness (n=137) 35/40 (87.5) 80/97 (82.5) 1.49 (0.51 to 4.35) 0.468
Distal upper limb weakness (n=135) 40/41 (97.6) 89/94 (94.7) 2.25 (0.25 to 19.86) 0.466
Distal lower limb weakness (n=125) 23/43 (53.5) 36/82 (43.9) 1.47 (0.70 to 3.08) 0.309
Dysphagia (n=303) 63/100 (63.0) 113/203 (55.7) 1.36 (0.83 to 2.22) 0.224
Facial weakness (n=90) 18/33 (54.6) 18/57 (31.6) 2.60 (1.07 to 6.29) 0.034†
Axial involvement (n=84) 9/26 (34.6) 10/58 (17.2) 2.54 (0.88 to 7.31) 0.084
Clinical evidence of polyneuropathy (n=103) 13/38 (34.2) 31/65 (47.7) 0.57 (0.25 to 1.31) 0.184
Figures in brackets represent within antibody group percentages. n represents data available for analysis per variable (of a total of 311). p Value is derived from logistic regression. Data
regarding certain variables (proximal upper limb weakness, facial weakness, symmetrical weakness and clinical evidence of polyneuropathy) were only available at either disease onset or
at last review.
*Adjusted (for age at disease onset, gender and comorbidities) OR 0.29, 95% CI 0.12 to 0.68, p=0.005.
†Adjusted (for age at disease onset, gender and comorbidities) OR 3.03, 95% CI 1.20 to 7.67, p=0.019.
Anti-cN-1A, anticytosolic 50-nucleotidase 1A.
Table 4 Autoantibody profile stratified by anti-cN-1A antibody status
Antibody Anti-cN-1A positive (%) Anti-cN-1A negative (%) OR (95% CI) p Value
Antinuclear antibodies (n=132) 1/47 (2.1) 1/85 (1.2) 1.83 (0.11 to 29.88) 0.673
Anti-DNA antibodies (n=119) 3/42 (7.1) 1/77 (1.3) 5.85 (0.59 to 58.07) 0.132
Anti-Sm antibodies (n=97) 0/33 (0.0) 1/64 (1.6) 1 –
Antineutrophil cytoplasmic antibodies (n=96) 0/32 (0.0) 0/64 (0.0) – –
Antimitochondrial antibodies (n=128) 0/41 (0.0) 0/87 (0.0) – –
Antiextractable nuclear antigens antibodies (n=102) 4/34 (11.8) 5/68 (7.4) 1.68 (0.42 to 6.71) 0.463
Anti-SSA (Ro) (n=228) 19/76 (25.0) 22/152 (14.5) 1.97 (0.99 to 3.92) 0.054
Anti-SSB (La) (n=228) 13/76 (17.1) 9/152 (5.9) 3.28 (1.33 to 8.07) 0.010*
(U1)RNP antibodies (n=223) 1/74 (1.4) 0/149 (0.0) 1 –
Antitopoisomerase I (Scl70) (n=222) 0/72 (0.0) 0/150 (0.0) – –
Anti-Jo1 (n=228) 1/76 (1.3) 0/152 (0.0) 1 –
Other myositis-specific antibody (OMSA)† (n=193) 0/60 (0.0) 1/133 (0.8) 1 –
Other myositis-associated antibody (OMAA) (n=128) 0/41 (0.0) 0/87 (0.0) – –
Figures in brackets represent within antibody group percentages. n represents data available for analysis per variable (of a total of 311). p Value is derived from logistic regression.
*Adjusted (for anti-SSA antibodies, presence of autoimmune disorders, age at disease onset, gender and comorbidities) OR 2.11, 95% CI 0.52 to 8.67, p=0.297.
†One patient found positive for anti-SRP antibodies. In this case, no relevant clinical correlation was identified, and the relevance of this finding is uncertain.
Anti-cN-1A, anticytosolic 50-nucleotidase 1A; OMAA, anti-Ku, anti-RNA polymerase I/II/III, anti-PM/SCL, anti-NOR90; OMSA, anti-TIF1 complex, anti-SAE, anti-NXP2, anti-MDA5, anti-SRP,
anti-Mi-2, anti-PL12, anti-PL7, anti-EJ, anti-KS, anti-OJ, anti-Zo.
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testing to differentiate IBM and mimicking diagnoses.22
However, the speciﬁcity of testing is limited by a high reactivity
in some other autoimmune and connective tissue diseases (in
36% of patients with Sjögren’s syndrome and in 20% with sys-
temic lupus erythematosus).22 24
The higher frequency of COX-negative ﬁbres, a feature of
mitochondrial dysfunction, indicates possible differences in
molecular pathways within the subgroups deﬁned by anti-cN-1A
antibody status. The reasons for increased mortality and the sug-
gestion of increased risk of death from respiratory cause are
unexplained, but these ﬁndings appear to agree with those of
Goyal et al18 who also found a more severe respiratory pheno-
type in the antibody-positive group. The lower frequency of
proximal upper limb weakness at presentation in the anti-cN-1A
antibody positive compared with antibody-negative group
remains unexplained.
This study represents the largest cohort of patients with IBM
and has only been achieved by an international collaborative
effort. Established IBM diagnostic criteria were used to include
patients for the analysis, a predeﬁned set of clinical data was
retrieved in each patient and all anti-cN-1A testing was per-
formed in one laboratory. However, there remain a number of
limitations. The study was retrospective and relied on the identi-
ﬁcation and recording of clinical characteristics by the treating
physicians. In the UK cohort, the recruiting physician (the
patient’s treating consultant neurologist or rheumatologist) was
asked to recall the symptoms that were present at the time of
disease onset when completing the pro forma at the time of
recruitment, and as such these details may be subject to recall
bias. While efforts to minimise missing data were made, data
were not complete for all study parameters in all cases, although
there was no evidence to suggest that this occurred in a system-
atic way. Analysis involved pooling of data from different
cohorts. There is potential for differences in data collection
methodology between cohorts (see online supplementary
appendix 1) to reduce the reliability of our ﬁndings. However, a
comparison of features between UK and non-UK cohorts where
pooled data were analysed has revealed largely comparable ﬁnd-
ings (see online supplementary table S1). Overall, we feel that
our pooled analysis has increased statistical power and
reduced the likelihood of statistical errors occurring.
Objective measurements of muscle strength (eg, dynamome-
try of the ﬁnger ﬂexors) could have improved sensitivity of
detection of weakness, but such methods were not available.
Also, this study did not perform a reanalysis of muscle
biopsy tissue. The cause of death was difﬁcult to establish in
some patients in the non-UK cohort, due to missing informa-
tion in the medical records, and in the UK cohort due to an
inability to match some patients to the nationally stored mor-
tality data held by the UK Health and Social Care
Information Centre.
In the future, anti-cN-1A autoantibody testing and
anti-cN-1A autoantibody status could be used in the diagnostic
workup of potential IBM cases, and there remains the oppor-
tunity to use anti-cN-1A antibody status in the construction of
future diagnostic criteria for IBM. However, the results of the
current study also suggest that distinct IBM subtypes may be
identiﬁed according to anti-cN1-A antibody status. Therefore,
serum anti-cN-1A testing might also be of use in the stratiﬁca-
tion of patients with IBM (eg, for clinical trials), rather than
purely as a diagnostic biomarker. A large prospective study with
a sufﬁcient duration of follow-up might offer potential to
further investigate the overall utility of anti-cN-1A antibody
testing in the clinical and research settings.
CONCLUSION
In this exploratory study, comparison of patients with IBM with
and without anti-cN-1A autoantibody reactivity identiﬁed differ-
ences in their mortality risk, clinical characteristics and histo-
pathological ﬁndings. The largest study of its kind has
demonstrated that anti-cN-1A antibody testing may, and over
and above its diagnostic value, be clinically useful to deﬁne dis-
tinct IBM subtypes.
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Excess COX-deficient fibres (n=185) 53/61 (86.9) 89/124 (71.8) 2.61 (1.13 to 6.03) 0.025*
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Atrophic fibres (n=176) 59/69 (85.5) 98/107 (91.6) 0.54 (0.21 to 1.41) 0.209
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Figures in brackets represent within antibody group percentages. n represents data available for analysis per variable (of a total of 311). p Value is derived from logistic regression.
*Adjusted (for age at disease onset, gender and comorbidities) OR 2.60, 95% CI 1.11 to 6.12, p=0.028. Adjusted (additionally for age at biopsy) OR 2.80, 95% CI 1.17 to 6.66, p=0.020.
†Includes amyloid (Congo Red or immunofluorescence), p62 (immunofluorescence) and TDP-43 (immunofluorescence).
‡15–21 nm tubulofilaments identified by electron microscopy.
Anti-cN-1A, anticytosolic 50-nucleotidase 1A; COX, cytochrome oxidase; MHC, major histocompatibility complex.
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